Literature DB >> 14726685

Knockdown of Chk1, Wee1 and Myt1 by RNA interference abrogates G2 checkpoint and induces apoptosis.

Yuli Wang1, Stuart J Decker, Judith Sebolt-Leopold.   

Abstract

Mammalian cells undergo cell cycle arrest in response to DNA damage due to the existence of multiple checkpoint response mechanisms. One such checkpoint pathway operating at the G(1) phase is frequently lost in cancer cells due to mutation of the p53 tumor suppressor gene. However, cancer cells often arrest at the G(2) phase upon DNA damage, due to activation of another checkpoint pathway that prevents the activation Cdc2 kinase. The kinases, Chk1, Wee1, and Myt1 are key regulators of this G(2) checkpoint, which act directly or indirectly to inhibit Cdc2 activity. Here we show that RNA interference (RNAi)-mediated downregulation of Wee1 kinase abrogated an Adriamycin trade mark -induced G(2) checkpoint in human cervical carcinoma Hela cells that are defective in G(1) checkpoint response. Wee1 downregulation sensitized HeLa cells to Adriamycin trade mark -induced apoptosis. Downregulation of Chk1 kinase in Hela cells also caused a significant amount of cell death in dependent of DNA damage. In contrast, Myt1 downregulation also abrogated Adriamycin trade mark -induced G(2) arrest but did not cause substantial apoptosis. Reduction in Wee1, Chk1, or Myt1 levels did not sensitize normal human mammary epithelial cells (HMEC) cells to Adriamycin trade mark -induced apoptosis unlike the situation in Hela cells. Our study reveals distinct roles for Chk1, Wee1, and Myt1 in G(2) checkpoint regulation. The data reported here support the attractiveness of Wee1 and Chk1 is as molecular targets for abrogating the G(2) DNA damage checkpoint arrest, a situation that may selectively sensitize p53-deficient tumor cells to radiation or chemotherapy treatment.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14726685     DOI: 10.4161/cbt.3.3.697

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN: 1538-4047            Impact factor:   4.742


  48 in total

1.  JLK1486, a Bis 8-Hydroxyquinoline-Substituted Benzylamine, Displays Cytostatic Effects in Experimental Gliomas through MyT1 and STAT1 Activation and, to a Lesser Extent, PPARγ Activation.

Authors:  Céline Bruyère; Sébastien Madonna; Gwendoline Van Goietsenoven; Véronique Mathieu; Jean Dessolin; Jean-Louis Kraus; Florence Lefranc; Robert Kiss
Journal:  Transl Oncol       Date:  2011-06-01       Impact factor: 4.243

Review 2.  Synthetic lethal interactions for the development of cancer therapeutics: biological and methodological advancements.

Authors:  Shinji Mizuarai; Hidehito Kotani
Journal:  Hum Genet       Date:  2010-10-26       Impact factor: 4.132

Review 3.  The human intra-S checkpoint response to UVC-induced DNA damage.

Authors:  William K Kaufmann
Journal:  Carcinogenesis       Date:  2009-09-30       Impact factor: 4.944

4.  Phase 0 Trial of AZD1775 in First-Recurrence Glioblastoma Patients.

Authors:  Nader Sanai; Jing Li; Julie Boerner; Karri Stark; Jianmei Wu; Seongho Kim; Alanna Derogatis; Shwetal Mehta; Harshil D Dhruv; Lance K Heilbrun; Michael E Berens; Patricia M LoRusso
Journal:  Clin Cancer Res       Date:  2018-05-24       Impact factor: 12.531

Review 5.  Wee1 kinase as a target for cancer therapy.

Authors:  Khanh Do; James H Doroshow; Shivaani Kummar
Journal:  Cell Cycle       Date:  2013-08-26       Impact factor: 4.534

Review 6.  GBM radiosensitizers: dead in the water…or just the beginning?

Authors:  Ranjit S Bindra; Anthony J Chalmers; Sydney Evans; Mark Dewhirst
Journal:  J Neurooncol       Date:  2017-07-31       Impact factor: 4.130

Review 7.  Targeting DNA repair and the cell cycle in glioblastoma.

Authors:  Brian M Alexander; Nancy Pinnell; Patrick Y Wen; Alan D'Andrea
Journal:  J Neurooncol       Date:  2011-11-24       Impact factor: 4.130

8.  Abrogating G₂/M checkpoint through WEE1 inhibition in combination with chemotherapy as a promising therapeutic approach for mesothelioma.

Authors:  Paola Indovina; Eleonora Marcelli; Domenico Di Marzo; Nadia Casini; Iris Maria Forte; Francesca Giorgi; Luigi Alfano; Francesca Pentimalli; Antonio Giordano
Journal:  Cancer Biol Ther       Date:  2014-01-14       Impact factor: 4.742

9.  Synthetic lethal RNAi screening identifies sensitizing targets for gemcitabine therapy in pancreatic cancer.

Authors:  David O Azorsa; Irma M Gonzales; Gargi D Basu; Ashish Choudhary; Shilpi Arora; Kristen M Bisanz; Jeffrey A Kiefer; Meredith C Henderson; Jeffrey M Trent; Daniel D Von Hoff; Spyro Mousses
Journal:  J Transl Med       Date:  2009-06-11       Impact factor: 5.531

10.  Discovery of gene expression-based pharmacodynamic biomarker for a p53 context-specific anti-tumor drug Wee1 inhibitor.

Authors:  Shinji Mizuarai; Kazunori Yamanaka; Hiraku Itadani; Tsuyoshi Arai; Toshihide Nishibata; Hiroshi Hirai; Hidehito Kotani
Journal:  Mol Cancer       Date:  2009-06-08       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.